Drug intelligence / Profile preview

Afomill

Development stage: Unknown
Lead developer: Montefarmaco
Administration: Ophthalmic

Overview

Afomill is a brand of ophthalmic solutions marketed as medical devices for the treatment of dry eye disease (DED) and ocular surface irritation. The product line includes various formulations, such as Afomill Lubricating Eye Drops, which contains 0.2% sodium hyaluronate (hyaluronic acid) and distilled chamomile water. Sodium hyaluronate acts as a physiological tear film substitute, utilizing its hydrophilic properties to retain water, stabilize the tear film, and reduce friction on the corneal surface. Afomill is also used as an add-on therapy to relieve ocular surface disease symptoms in patients undergoing glaucoma treatment, helping to alleviate sensations of burning, fatigue, and redness.

Brand names: AfomillAfomill Lubricating Eye DropsAfomill Refreshing SoothingAfomill Anti-redness Eye Drops

Beyond the preview

Go deeper on Afomill.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Afomill.

Explore the full profile